Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To estimate the rate of freedom from progression for at least 3 cycles in patients with relapsed mantle cell lymphoma who have received enzastaurin.

Outcome Time Frame:

baseline, after 3 cycles

Safety Issue:

No

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)

Investigator Role:

Study Director

Investigator Affiliation:

Eli Lilly and Company

Authority:

United States: Food and Drug Administration

Study ID:

8360

NCT ID:

NCT00088205

Start Date:

March 2004

Completion Date:

May 2008

Related Keywords:

• Mantle-Cell Lymphoma
• Lymphoma
• Lymphoma, Mantle-Cell